List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8012387/publications.pdf Version: 2024-02-01

110 papers	10,619 citations	117625 34 h-index	³⁴⁹⁸⁶ 98 g-index
112	112	112	13955
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	The global burden of hip and knee osteoarthritis: estimates from the Global Burden of Disease 2010 study. Annals of the Rheumatic Diseases, 2014, 73, 1323-1330.	0.9	2,433
2	The global burden of rheumatoid arthritis: estimates from the Global Burden of Disease 2010 study. Annals of the Rheumatic Diseases, 2014, 73, 1316-1322.	0.9	820
3	Global, regional and national burden of osteoarthritis 1990-2017: a systematic analysis of the Global Burden of Disease Study 2017. Annals of the Rheumatic Diseases, 2020, 79, 819-828.	0.9	732
4	Global low back pain prevalence and years lived with disability from 1990 to 2017: estimates from the Global Burden of Disease Study 2017. Annals of Translational Medicine, 2020, 8, 299-299.	1.7	662
5	Developing Core Outcome Measurement Sets for Clinical Trials: OMERACT Filter 2.0. Journal of Clinical Epidemiology, 2014, 67, 745-753.	5.0	625
6	The global burden of neck pain: estimates from the Global Burden of Disease 2010 study. Annals of the Rheumatic Diseases, 2014, 73, 1309-1315.	0.9	518
7	Global, regional and national burden of rheumatoid arthritis 1990–2017: a systematic analysis of the Global Burden of Disease study 2017. Annals of the Rheumatic Diseases, 2019, 78, 1463-1471.	0.9	444
8	Musculoskeletal Health Conditions Represent a Global Threat to Healthy Aging: A Report for the 2015 World Health Organization World Report on Ageing and Health. Gerontologist, The, 2016, 56, S243-S255.	3.9	437
9	Burden of disability due to musculoskeletal (MSK) disorders. Best Practice and Research in Clinical Rheumatology, 2014, 28, 353-366.	3.3	384
10	Osteoarthritis in 2020 and beyond: a Lancet Commission. Lancet, The, 2020, 396, 1711-1712.	13.7	355
11	Reducing the global burden of musculoskeletal conditions. Bulletin of the World Health Organization, 2018, 96, 366-368.	3.3	295
12	The global burden of other musculoskeletal disorders: estimates from the Global Burden of Disease 2010 study. Annals of the Rheumatic Diseases, 2014, 73, 1462-1469.	0.9	220
13	The global burden of gout: estimates from the Global Burden of Disease 2010 study. Annals of the Rheumatic Diseases, 2014, 73, 1470-1476.	0.9	206
14	Endogenous MMP-9 and not MMP-2 promotes rheumatoid synovial fibroblast survival, inflammation and cartilage degradation. Rheumatology, 2014, 53, 2270-2279.	1.9	155
15	Glucosamine and chondroitin for knee osteoarthritis: a double-blind randomised placebo-controlled clinical trial evaluating single and combination regimens. Annals of the Rheumatic Diseases, 2015, 74, 851-858.	0.9	152
16	Defining an International Standard Set of Outcome Measures for Patients With Hip or Knee Osteoarthritis: Consensus of the International Consortium for Health Outcomes Measurement Hip and Knee Osteoarthritis Working Group. Arthritis Care and Research, 2016, 68, 1631-1639.	3.4	107
17	Biologics and cardiovascular events in inflammatory arthritis: a prospective national cohort study. Arthritis Research and Therapy, 2018, 20, 171.	3.5	105
18	Prevalence, Incidence, and Years Lived With Disability Due to Gout and Its Attributable Risk Factors for 195 Countries and Territories 1990–2017: A Systematic Analysis of the Global Burden of Disease Study 2017. Arthritis and Rheumatology, 2020, 72, 1916-1927.	5.6	103

#	Article	IF	CITATIONS
19	OMERACT Filter 2.1: Elaboration of the Conceptual Framework for Outcome Measurement in Health Intervention Studies. Journal of Rheumatology, 2019, 46, 1021-1027.	2.0	97
20	An overview of clinical guidelines for the management of vertebral compression fracture: a systematic review. Spine Journal, 2017, 17, 1932-1938.	1.3	85
21	The Cost of Osteoporosis, Osteopenia, and Associated Fractures in Australia in 2017. Journal of Bone and Mineral Research, 2019, 34, 616-625.	2.8	80
22	Establishing a Core Domain Set to Measure Rheumatoid Arthritis Flares: Report of the OMERACT 11 RA Flare Workshop. Journal of Rheumatology, 2014, 41, 799-809.	2.0	65
23	Core Domain Set Selection According to OMERACT Filter 2.1: The OMERACT Methodology. Journal of Rheumatology, 2019, 46, 1014-1020.	2.0	65
24	When, Where and How Osteoporosis-Associated Fractures Occur: An Analysis from the Global Longitudinal Study of Osteoporosis in Women (GLOW). PLoS ONE, 2013, 8, e83306.	2.5	63
25	Instrument Selection Using the OMERACT Filter 2.1: The OMERACT Methodology. Journal of Rheumatology, 2019, 46, 1028-1035.	2.0	61
26	Effect of Intravenous Zoledronic Acid on Tibiofemoral Cartilage Volume Among Patients With Knee Osteoarthritis With Bone Marrow Lesions. JAMA - Journal of the American Medical Association, 2020, 323, 1456.	7.4	59
27	Reliability of joint count assessment in rheumatoid arthritis: A systematic literature review. Seminars in Arthritis and Rheumatism, 2014, 43, 721-729.	3.4	57
28	Skin Barrier Dysregulation in Psoriasis. International Journal of Molecular Sciences, 2021, 22, 10841.	4.1	57
29	Identifying flares in rheumatoid arthritis: reliability and construct validation of the OMERACT RA Flare Core Domain Set. RMD Open, 2016, 2, e000225.	3.8	54
30	Global, regional, and national burden of other musculoskeletal disorders 1990–2017: results from the Global Burden of Disease Study 2017. Rheumatology, 2021, 60, 855-865.	1.9	52
31	Cost of joint replacement surgery for osteoarthritis: the patients' perspective. Journal of Rheumatology, 2002, 29, 1006-14.	2.0	52
32	Developing a minimum standard of care for treating people with osteoarthritis of the hip and knee. Best Practice and Research in Clinical Rheumatology, 2010, 24, 121-145.	3.3	51
33	Feasibility and Domain Validation of Rheumatoid Arthritis (RA) Flare Core Domain Set: Report of the OMERACT 2014 RA Flare Group Plenary. Journal of Rheumatology, 2015, 42, 2185-2189.	2.0	40
34	Effects of pentosan polysulfate in osteoarthritis of the knee: A randomized, double-blind, placebo-controlled pilot study. Current Therapeutic Research, 2005, 66, 552-571.	1.2	38
35	Factors associated with oral glucocorticoid use in patients with rheumatoid arthritis: a drug use study from a prospective national biologics registry. Arthritis Research and Therapy, 2017, 19, 253.	3.5	32
36	Increase in Fracture Risk Following Unintentional Weight Loss in Postmenopausal Women: The Global Longitudinal Study of Osteoporosis in Women. Journal of Bone and Mineral Research, 2016, 31, 1466-1472.	2.8	29

#	Article	IF	CITATIONS
37	Defining Flare in Osteoarthritis of the Hip and Knee: A Systematic Literature Review — OMERACT Virtual Special Interest Group. Journal of Rheumatology, 2017, 44, 1920-1927.	2.0	27
38	Health systems strengthening to arrest the global disability burden: empirical development of prioritised components for a global strategy for improving musculoskeletal health. BMJ Global Health, 2021, 6, e006045.	4.7	26
39	Content and Construct Validity, Reliability, and Responsiveness of the Rheumatoid Arthritis Flare Questionnaire: OMERACT 2016 Workshop Report. Journal of Rheumatology, 2017, 44, 1536-1543.	2.0	25
40	Web-Based Study of Risk Factors for Pain Exacerbation in Osteoarthritis of the Knee (SPARK-Web): Design and Rationale. JMIR Research Protocols, 2015, 4, e80.	1.0	25
41	Malignancy risk in Australian rheumatoid arthritis patients treated with anti-tumour necrosis factor therapy: analysis of the Australian Rheumatology Association Database (ARAD) prospective cohort study. BMC Musculoskeletal Disorders, 2015, 16, 309.	1.9	24
42	Treating osteoporosis. Australian Prescriber, 2016, 39, 40-46.	1.0	24
43	Outcome Measures in Rheumatology - Interventions for medication Adherence (OMERACT-Adherence) Core Domain Set for Trials of Interventions for Medication Adherence in Rheumatology: 5 Phase Study Protocol. Trials, 2018, 19, 204.	1.6	23
44	Developing a Preliminary Definition and Domains of Flare in Knee and Hip Osteoarthritis (OA): Consensus Building of the Flare-in-OA OMERACT Group. Journal of Rheumatology, 2019, 46, 1188-1191.	2.0	23
45	Malignancy risk in Australian rheumatoid arthritis patients treated with anti-tumour necrosis factor therapy: an update from the Australian Rheumatology Association Database (ARAD) prospective cohort study. BMC Rheumatology, 2019, 3, 1.	1.6	23
46	Treatment of chronic diabetic lower leg ulcers with activated protein C: a randomised placeboâ€controlled, doubleâ€blind pilot clinical trial. International Wound Journal, 2015, 12, 422-427.	2.9	22
47	A protocol for a multicentre, randomised, double-blind, placebo-controlled trial to compare the effect of annual infusions of zoledronic acid to placebo on knee structural change and knee pain over 24Âmonths in knee osteoarthritis patients – ZAP2. BMC Musculoskeletal Disorders, 2018, 19, 217.	1.9	22
48	Toward the Development of a Core Set of Outcome Domains to Assess Shared Decision-making Interventions in Rheumatology: Results from an OMERACT Delphi Survey and Consensus Meeting. Journal of Rheumatology, 2017, 44, 1544-1550.	2.0	21
49	Consensus Building in OMERACT: Recommendations for Use of the Delphi for Core Outcome Set Development. Journal of Rheumatology, 2019, 46, 1041-1046.	2.0	21
50	Relationship of Buckling and Knee Injury to Pain Exacerbation in Knee Osteoarthritis: A Web-Based Case-Crossover Study. Interactive Journal of Medical Research, 2016, 5, e17.	1.4	21
51	Can occupational therapy intervention play a part in maintaining independence and quality of life in older people? A randomised controlled trial. Australian and New Zealand Journal of Public Health, 1996, 20, 574-578.	1.8	19
52	Patient and Caregiver Priorities for Medication Adherence in Gout, Osteoporosis, and Rheumatoid Arthritis: Nominal Group Technique. Arthritis Care and Research, 2020, 72, 1410-1419.	3.4	19
53	Dermal Fibroblast Heterogeneity and Its Contribution to the Skin Repair and Regeneration. Advances in Wound Care, 2022, 11, 87-107.	5.1	18
54	Activated protein C targets immune cells and rheumatoid synovial fibroblasts to prevent inflammatory arthritis in mice. Rheumatology, 2019, 58, 1850-1860.	1.9	17

#	Article	IF	CITATIONS
55	Clinical risk factors associated with radiographic osteoarthritis progression among people with knee pain: a longitudinal study. Arthritis Research and Therapy, 2021, 23, 160.	3.5	16
56	Consensus on the Need for a Hierarchical List of Patient-reported Pain Outcomes for Metaanalyses of Knee Osteoarthritis Trials: An OMERACT Objective. Journal of Rheumatology, 2015, 42, 1971-1975.	2.0	15
57	Scope of Outcomes in Trials and Observational Studies of Interventions Targeting Medication Adherence in Rheumatic Conditions: A Systematic Review. Journal of Rheumatology, 2020, 47, 1565-1574.	2.0	15
58	The need for adaptable global guidance in health systems strengthening for musculoskeletal health: a qualitative study of international key informants. Global Health Research and Policy, 2021, 6, 24.	3.6	15
59	ls osteoporosis undertreated after minimal trauma fracture?. Medical Journal of Australia, 2001, 174, 663-664.	1.7	14
60	The completeness of electronic medical record data for patients with Type 2 Diabetes in primary care and its implications for computer modelling of predicted clinical outcomes. Primary Care Diabetes, 2016, 10, 352-359.	1.8	14
61	Vertebral fragility fractures – How to treat them?. Best Practice and Research in Clinical Rheumatology, 2019, 33, 227-235.	3.3	14
62	OMERACT Development of a Core Domain Set of Outcomes for Shared Decision-making Interventions. Journal of Rheumatology, 2019, 46, 1409-1414.	2.0	14
63	Biochemical Markers of Acute Myocardial Infarction: Strategies for Improving Their Clinical Usefulness. Annals of Clinical Biochemistry, 1998, 35, 393-399.	1.6	13
64	Endorsement of the OMERACT core domain set for shared decision making interventions in rheumatology trials: Results from a multi-stepped consensus-building approach. Seminars in Arthritis and Rheumatism, 2021, 51, 593-600.	3.4	13
65	Endorsement of the domains of knee and hip osteoarthritis (OA) flare: A report from the OMERACT 2020 inaugural virtual consensus vote from the flares in OA working group. Seminars in Arthritis and Rheumatism, 2021, 51, 618-622.	3.4	12
66	Rheumatoid arthritis is a preventable disease: 11 ways to reduce your patients' risk. Internal Medicine Journal, 2022, 52, 711-716.	0.8	12
67	The global burden of musculoskeletal conditions – Why is it important?. Best Practice and Research in Clinical Rheumatology, 2010, 24, 721.	3.3	11
68	Stiffness Is the Cardinal Symptom of Inflammatory Musculoskeletal Diseases, Yet Still Variably Measured: Report from the OMERACT 2016 Stiffness Special Interest Group. Journal of Rheumatology, 2017, 44, 1904-1910.	2.0	11
69	Identifying Provisional Generic Contextual Factor Domains for Clinical Trials in Rheumatology: Results from an OMERACT Initiative. Journal of Rheumatology, 2019, 46, 1159-1163.	2.0	11
70	National Osteoarthritis Strategy brief report: Living well with osteoarthritis. Australian Journal of General Practice, 2020, 49, 438-442.	0.8	11
71	A randomized controlled trial for improving patient self-assessment of synovitis in rheumatoid arthritis with education by ultrasonography: the RAEUS Study. Rheumatology, 2015, 54, 1161-1169.	1.9	10
72	Prevalence and determinants of physical activity and sedentary behaviour before and up to 12 months after total knee replacement: a longitudinal cohort study. Clinical Rehabilitation, 2018, 32, 1271-1283.	2.2	10

#	Article	IF	CITATIONS
73	Factors associated with commencing and ceasing opioid therapy in patients with rheumatoid arthritis. Seminars in Arthritis and Rheumatism, 2019, 49, 351-357.	3.4	10
74	Activated Protein C Inhibits Proliferation and Tumor Necrosis Factor α-Stimulated Activation of p38, c-Jun NH2-Terminal Kinase (JNK) and Akt in Rheumatoid Synovial Fibroblasts. Molecular Medicine, 2013, 19, 324-331.	4.4	9
75	Zoledronic acid plus methylprednisolone <i>versus</i> zoledronic acid or placebo in symptomatic knee osteoarthritis: a randomized controlled trial. Therapeutic Advances in Musculoskeletal Disease, 2019, 11, 1759720X1988005.	2.7	9
76	The association between change in bone marrow lesion size and change in tibiofemoral cartilage volume and knee symptoms. Rheumatology, 2021, 60, 2791-2800.	1.9	9
77	Estimating the Prevalence of Knee Pain and the Association between Illness Perception Profiles and Self-Management Strategies in the Frederiksberg Cohort of Elderly Individuals with Knee Pain: A Cross-Sectional Study. Journal of Clinical Medicine, 2021, 10, 668.	2.4	9
78	Disability burden due to musculoskeletal conditions and low back pain in Australia: findings from GBD 2019. Chiropractic & Manual Therapies, 2022, 30, 22.	1.5	9
79	Improving Benefit-harm Assessment of Therapies from the Patient Perspective: OMERACT Premeeting Toward Consensus on Core Sets for Randomized Controlled Trials. Journal of Rheumatology, 2019, 46, 1053-1058.	2.0	8
80	Patient Perspectives on DMARD Safety Concerns in Rheumatology Trials: Results from Inflammatory Arthritis Patient Focus Groups and OMERACT Attendees Discussion. Journal of Rheumatology, 2019, 46, 1168-1172.	2.0	8
81	Early development of the Australia and New Zealand Musculoskeletal Clinical Trials Network. Internal Medicine Journal, 2020, 50, 17-23.	0.8	8
82	The burden of osteoarthritis: self-reported severity in the KHOALA population-based cohort. Rheumatology, 2020, 59, 2368-2373.	1.9	8
83	Osteoarthritis in 2020 and beyond $\hat{a} \in$ "Authors' reply. Lancet, The, 2021, 397, 1060.	13.7	8
84	Core Outcome Sets Specifically for Longterm Observational Studies: OMERACT Special Interest Group Update in Rheumatoid Arthritis. Journal of Rheumatology, 2019, 46, 1164-1167.	2.0	7
85	Oral Complementary Medicine Use among People with Inflammatory Arthritis: An Australian Rheumatology Association Database Analysis. International Journal of Rheumatology, 2020, 2020, 1-9.	1.6	7
86	OMERACT consensus-based operational definition of contextual factors in rheumatology clinical trials: A mixed methods study. Seminars in Arthritis and Rheumatism, 2021, 51, 601-606.	3.4	7
87	Development and validation of the Flare-OA questionnaire for measuring flare in knee and hip osteoarthritis. Osteoarthritis and Cartilage, 2022, 30, 689-696.	1.3	7
88	Identifying Possible Outcome Domains from Existing Outcome Measures to Inform an OMERACT Core Domain Set for Safety in Rheumatology Trials. Journal of Rheumatology, 2019, 46, 1173-1178.	2.0	6
89	Towards consensus in defining and handling contextual factors within rheumatology trials: an initial qualitative study from an OMERACT working group. Annals of the Rheumatic Diseases, 2021, 80, 242-249.	0.9	6
90	Patterns of biologic and targeted-synthetic disease-modifying antirheumatic drug use in rheumatoid arthritis in Australia. Rheumatology, 2022, 61, 3939-3951.	1.9	6

#	Article	IF	CITATIONS
91	Addressing Challenges in Developing a Core Domain Set in Adherence Interventions in Rheumatology: A Report from the OMERACT-Adherence Group. Journal of Rheumatology, 2019, 46, 1202-1206.	2.0	5
92	Prevalence of self-reported knee symptoms and management strategies among elderly individuals from Frederiksberg municipality: protocol for a prospective and pragmatic Danish cohort study. BMJ Open, 2019, 9, e028087.	1.9	5
93	Biopsychosocial Rehabilitation for Inflammatory Arthritis and Osteoarthritis Patients: A Systematic Review and Metaâ€Analysis of Randomized Trials. Arthritis Care and Research, 2023, 75, 423-436.	3.4	5
94	Activated Protein C Protects against Murine Contact Dermatitis by Suppressing Protease-Activated Receptor 2. International Journal of Molecular Sciences, 2022, 23, 516.	4.1	5
95	Association between osteoarthritis-related serum biochemical markers over 11 years and knee MRI-based imaging biomarkers in middle-aged adults. Osteoarthritis and Cartilage, 2022, 30, 756-764.	1.3	5
96	Train High Eat Low for Osteoarthritis study (THE LO study): protocol for a randomized controlled trial. Journal of Physiotherapy, 2015, 61, 217.	1.7	4
97	Investigating Dimensions of Stiffness in Rheumatoid and Psoriatic Arthritis: The Australian Rheumatology Association Database Registry and OMERACT Collaboration. Journal of Rheumatology, 2019, 46, 1462-1469.	2.0	4
98	Healthcare access and attitudes towards telehealth during the early phase of the <scp>COVID</scp> â€19 pandemic among an Australian cohort with inflammatory arthritis. Internal Medicine Journal, 2021, 51, 788-792.	0.8	4
99	Development of a patient-centered core domain set for prospective observational longitudinal outcome studies in rheumatoid arthritis: an OMERACT initiative. Seminars in Arthritis and Rheumatism, 2021, 51, 1113-1116.	3.4	4
100	Post-operative outcomes of inflammatory thoracic aortitis: a study of 41 patients from a cohort of 1119 surgical cases. Clinical Rheumatology, 2022, 41, 1219-1226.	2.2	4
101	Using computer modelled life expectancy to evaluate the impact of Australian Primary Care Incentive programs for patients with type 2 diabetes. Diabetes Research and Clinical Practice, 2015, 109, 319-325.	2.8	3
102	Response to: †Overweight/obesity and vitamin D deficiency contribute to the global burden of low back pain' by Professor Grant. Annals of the Rheumatic Diseases, 2014, 73, e49-e49.	0.9	2
103	A fluoroscopic-guided intraarticular corticosteroid injection improved pain in osteoarthritis of the hip. ACP Journal Club, 2008, 148, 13.	0.1	2
104	Quantitative heel ultrasound as a predictor for osteoporosis. Medical Journal of Australia, 2000, 172, 245-247.	1.7	1
105	Researchers' perspectives on methodological challenges and outcomes selection in interventional studies targeting medication adherence in rheumatic diseases: an OMERACT-adherence study. BMC Rheumatology, 2021, 5, 26.	1.6	1
106	Surgery and physical therapy did not differ for function in meniscal tears with knee osteoarthritis. Annals of Internal Medicine, 2013, 159, JC13.	3.9	0
107	25×25 strategy for the burden of non-communicable diseases. The Lancet Global Health, 2014, 2, e320.	6.3	0
108	Patient Perspectives on Outcome Domains of Medication Adherence Trials in Inflammatory Arthritis: An International OMERACT Focus Group Study. Journal of Rheumatology, 2021, 48, 1480-1487.	2.0	0

#	Article	IF	CITATIONS
109	OMERACT 2020: A virtual (R)evolution. Seminars in Arthritis and Rheumatism, 2021, 51, 588-592.	3.4	Ο
110	A fluoroscopic-guided intraarticular corticosteroid injection improved pain in osteoarthritis of the hip. ACP Journal Club, 2008, 148, 13.	0.1	0